JWH-018

Coronary artery disease, Heart failure, Arrhythmias, Cerebrovascular disease, Hypertension

Tachycardia is the most consistently reported cardiovascular adverse effect, documented in 37–77% of emergency department presentations involving synthetic cannabinoids. Myocardial infarction and ischemic stroke are documented but rare. Individuals with pre-existing cardiovascular disease face compounded risk from CB1-mediated sympathetic activation.

Epilepsy, Seizure disorders, History of febrile seizures

JWH-018 produces seizures in mice via a CB1-mediated mechanism with greater convulsant potency than pentylenetetrazol. Critically, these seizures are resistant to benzodiazepine (diazepam) treatment, meaning standard seizure management protocols may be inadequate. Individuals with epilepsy or other seizure disorders face elevated risk from both the seizurogenic potential and the potential inadequacy of rescue medication.

Schizophrenia, Schizoaffective disorder, Psychotic disorders NOS, Family history of schizophrenia spectrum disorders

JWH-018 is a full CB1 agonist administered without CBD — both factors independently elevate psychosis risk relative to cannabis. Every-Palmer (2011) documented psychotic exacerbations in a psychiatric population using JWH-018. Van Amsterdam et al. (2015) confirmed the class-level mechanism. Individuals with personal or family history of psychosis or schizophrenia spectrum disorders face significantly elevated risk of acute psychotic episodes.

CYP2C9*2 carriers, CYP2C9*3 carriers, CYP2C9 poor metabolizers

JWH-018 is primarily metabolized by CYP2C9. Individuals carrying CYP2C9*3 (present in ~6–10% of European populations) experience >80% reduced enzyme activity, leading to markedly increased JWH-018 plasma concentrations and prolonged effects. This pharmacogenomic variation represents a population-level toxicity risk factor.

Pregnancy, Planned pregnancy

No human or animal reproductive toxicity data exists for JWH-018. The endocannabinoid system is involved in fetal neurodevelopment, placental function, and implantation. Full CB1 agonism by JWH-018, without the moderating influence of partial agonism or CBD, presents a theoretical risk to fetal development. This is a class-level cannabinoid concern, not JWH-018-specific evidence.

Adolescence (under 18)

Adolescents show higher vulnerability to cannabinoid-induced psychotic symptoms and neurodevelopmental disruption. Full CB1 agonism in the developing brain may produce lasting alterations in synaptic architecture. The endocannabinoid system plays a critical role in adolescent neural circuit refinement.

Benzodiazepine use, Opioid use, Alcohol intoxication, Sedative-hypnotic use

Co-administration with other CNS depressants (benzodiazepines, opioids, alcohol, sedative-hypnotics) may produce additive sedation, respiratory depression, and impaired consciousness assessment. This is a class-inferred pharmacodynamic interaction not specifically studied for JWH-018.